Close Menu

NEW YORK (GenomeWeb) – Investigators have begun to report on new applications of Vortex Bioscience's circulating tumor cell platform, which it commercialized late last year as the VTX-1. Recent reports have included data on existing biomarkers like EGFR and PD-L1, as well as newer investigations into things like the functioning of cells, which would be impossible without the system's ability to separate and partition viable CTCs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Oct
31
Sponsored by
PerkinElmer

This webinar will provide an overview of how the Center for Applied Genomics at Children's Hospital of Philadelphia has optimized its next-generation sequencing (NGS) workflow using a combination of PerkinElmer's Sciclone automation technology and target capture chemistry from Twist Bioscience.